In our quest to find better solutions in asthma, the Mundipharma global network of independent associated companies continues to invest in research into patient needs to identify and shape new ways of helping people with asthma to recognize, understand and better manage their condition and lead fuller lives. Gathering real-world data gives us the insight we need to develop new treatment options.
Working together with leading respiratory experts, we initiated the REALISE™ (REcognise Asthma and LInk to Symptoms and Experience) survey to uncover some of the underlying reasons for sub-optimal asthma control in Europe. REALISE™ was one of the largest surveys of its kind and was conducted across 11 European countries in 8,000 people with asthma aged 18–50 who use social media. A number of psychological factors were shown to affect a patient’s experience of asthma, such as identity, recognition of symptoms, confidence in disease management and perceptions towards inhaler use, highlighting the significant yet underestimated role patient attitudes and behaviors play in asthma management.
We are very proud of the differences being made to patients’ lives. By continuing to listen to the needs of all stakeholders, we can help find and develop real-world solutions for better breathing. The continued success and future of respiratory at Mundipharma will be driven by a heightened focus on understanding and recognising differences in attitudes and behaviors, including the important role that the choice of device can make to patient acceptance and adherence, and on collaboration with the medical community and patient groups. Together, we can enable significant advances towards improving disease management and facilitate the development of tailored asthma management strategies, with patients’ needs at the center.
What is respiratory disease?
Adult respiratory diseases in the developing world are a major burden in terms of morbidity and mortality and, particularly as related to chronic respiratory disease, are of increasing concern. These diseases fall into four categories: acute diseases, such as pneumonia and influenza; chronic diseases, such as chronic obstructive pulmonary disease (COPD) and asthma; occupational lung diseases, such as byssinosis, asbestosis, and coal worker's pneumoconiosis; and other parenchymal lung diseases, such as immune-related lung diseases.
What are the Chronic Respiratory Diseases?
Chronic respiratory diseases (CRDs) are diseases of the airways and other structures of the lung. Some of the most common are chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases and pulmonary hypertension. In addition to tobacco smoke, other risk factors include air pollution, occupational chemicals and dusts, and frequent lower respiratory infections during childhood. CRDs are not curable, however, various forms of treatment that help dilate major air passages and improve shortness of breath can help control symptoms and increase the quality of life for people with the disease. Approximately 235 million people suffer from asthma, a common disease among children.2
What are the symptoms of Asthma and COPD?
Asthma is a chronic, noncommunicable disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. Symptoms may occur several times in a day or week in affected individuals, and for some people become worse during physical activity or at night. Asthma is the most common chronic disease among children. 2 COPD is not one single disease but an umbrella term used to describe chronic lung diseases that cause limitations in lung airflow. The most common symptoms of COPD are breathlessness, or a ‘need for air’, excessive sputum production and a chronic cough. 2
What are the risk factors of Asthma?
Risk factors for chronic respiratory diseases include tobacco smoking (including second-hand smoke), air pollution, allergens and occupational risks. Outdoor air pollution and indoor air pollution (often caused by cooking with solid fuels) are also common causes. 2
How to treat Asthma and COPD?
Appropriate management of asthma through medications like inhaled corticosteroids can control the progression of the disease and reduce deaths. Daily, long-term medication is required for people with persistent symptoms and triggering settings should be avoided.2
Chronic obstructive pulmonary disease is confirmed by a spirometry test, which measures how much and how quickly a person can forcibly exhale air. Symptoms can be treated through medical and physical treatments; however, with COPD in people who smoke tobacco, the most effective treatment available is the cessation of smoking. This can slow down the progression of the disease and decrease COPDrelated deaths. Some people also find positive effects using inhaled corticosteroid medicines. 2
- Speizer FE, Horton S, Batt J, et al. Respiratory Diseases of Adults. In: Jamison DT, Breman JG, Measham AR, et al., editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 35. Available from: https://www.ncbi.nlm.nih.gov/books/NBK11773/ Co-published by Oxford University Press, New York.